Biosimilars Market to See Competition Rise: Pfizer, Inc., Reddy’s Laboratories Ltd.
Biosimilars
Market Overview:
The Biosimilars
Market
is projected to be worth USD 70.14
Billion by 2028, registering a CAGR of 24.3%
CAGR during the forecast period (2022-2028), the market was valued at USD 15.30 Billion in 2021.
The market refers to the production
and sale of biosimilars, which are biological products that are highly similar
to and have no clinically meaningful differences from an existing FDA-approved
biological product. Biosimilars are used to treat a wide range of diseases,
including cancer, autoimmune disorders, and infectious diseases.
The biosimilars market is primarily
propelled by several factors such as the high incidence of chronic diseases,
the expensive nature of biologic drugs, and the need to curtail healthcare
costs. It offer an economical alternative to biologic drugs, which can be
expensive due to their complex manufacturing procedures. Moreover, the lapse of
patents for several biologic drugs has created a favorable environment for
biosimilar manufacturers to make their way into the market.
There is a growing demand for
biosimilars in emerging economies due to the high prevalence of chronic
diseases, and this is driving investment in their development and
manufacturing. Moreover, the rising trend towards personalized medicine, which
involves customized treatment plans using biosimilars to cater to the specific
needs of individual patients, is expected to create significant growth
opportunities for the market in the future.
Get Sample
Report Here: https://marketresearchcommunity.com/sample-request/?rid=445
Market
Segment:
By Type
·
Human
growth hormone
·
Erythropoietin
·
Monoclonal
antibodies
·
Insulin
·
Granulocyte-Colony
Stimulating Factor
·
Others
By
Application
·
Blood
disorders
·
Oncology
diseases
·
Chronic
and autoimmune diseases
·
Others
Europe is the largest market for
biosimilars, owing to the favorable regulatory environment and the presence of
several biosimilar manufacturers in the region. The region has been at the
forefront of biosimilar development and has established a robust regulatory
framework to ensure the safety and efficacy of biosimilars.
The biosimilars market Report is expected to witness
significant growth during the forecast period, driven by the increasing demand
for cost-effective biologic drugs, the patent expiry of several biologic drugs,
and the growing investments in biosimilar development and manufacturing.
Contact Us:
Market
Research Community
sales@marketresearchcommunity.com
Comments
Post a Comment